GERN Fundamental Analysis - GERON CORP

Fundamental Rating

Overall GERN gets a fundamental rating of 3 out of 10. We evaluated GERN against 555 industry peers in the Biotechnology industry. While GERN seems to be doing ok healthwise, there are quite some concerns on its profitability. GERN shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

GERN had negative earnings in the past year.

GERN had a negative operating cash flow in the past year.

In the past 5 years GERN always reported negative net income.

GERN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -24.72%, GERN is in the better half of the industry, outperforming 73.51% of the companies in the same industry.

GERN's Return On Equity of -51.83% is fine compared to the rest of the industry. GERN outperforms 64.32% of its industry peers.

		Industry Rank	Sector Rank
ROA	-24.72%
ROE	-51.83%
ROIC	N/A

ROA(3y)-50.19%

ROA(5y)-45.98%

ROE(3y)-104.64%

ROE(5y)-88.33%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 97.88%, GERN belongs to the best of the industry, outperforming 97.84% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for GERN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	97.88%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for GERN has been increased compared to 1 year ago.

The number of shares outstanding for GERN has been increased compared to 5 years ago.

GERN has a better debt/assets ratio than last year.

2.2 Solvency

GERN has an Altman-Z score of -2.18. This is a bad value and indicates that GERN is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -2.18, GERN perfoms like the industry average, outperforming 51.71% of the companies in the same industry.

GERN has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.

GERN's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. GERN is outperformed by 72.97% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF	N/A
Altman-Z	-2.18

ROIC/WACCN/A

WACC8.45%

2.3 Liquidity

GERN has a Current Ratio of 7.87. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 7.87, GERN is in the better half of the industry, outperforming 69.55% of the companies in the same industry.

A Quick Ratio of 6.97 indicates that GERN has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 6.97, GERN is in the better half of the industry, outperforming 66.85% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.87
Quick Ratio	6.97

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.00% over the past year.

The Revenue has grown by 22393.81% in the past year. This is a very strong growth!

Measured over the past years, GERN shows a very strong growth in Revenue. The Revenue has been growing by 178.45% on average per year.

EPS 1Y (TTM)40%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.67%

Revenue 1Y (TTM)22393.81%

Revenue growth 3Y281.2%

Revenue growth 5Y178.45%

Sales Q2Q%12927.3%

3.2 Future

Based on estimates for the next years, GERN will show a very strong growth in Earnings Per Share. The EPS will grow by 40.11% on average per year.

Based on estimates for the next years, GERN will show a very strong growth in Revenue. The Revenue will grow by 64.14% on average per year.

EPS Next Y51.86%

EPS Next 2Y35.39%

EPS Next 3Y29.21%

EPS Next 5Y40.11%

Revenue Next Year163.93%

Revenue Next 2Y102.27%

Revenue Next 3Y80.35%

Revenue Next 5Y64.14%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GERN. In the last year negative earnings were reported.

Also next year GERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as GERN's earnings are expected to grow with 29.21% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.39%

EPS Next 3Y29.21%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GERN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GERON CORP

NASDAQ:GERN (6/30/2025, 6:17:35 PM)

After market: 1.42 +0.01 (+0.71%)

1.41

-0.08 (-5.37%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-07 2025-05-07/bmo

Earnings (Next)08-06 2025-08-06/bmo

Inst Owners80.93%

Inst Owner Change4.26%

Ins Owners0.08%

Ins Owner Change16.95%

Market Cap898.06M

Analysts81.33

Price Target3.76 (166.67%)

Short Float %10.15%

Short Ratio5.54

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)17.86%

Min EPS beat(2)13.34%

Max EPS beat(2)22.38%

EPS beat(4)4

Avg EPS beat(4)23.71%

Min EPS beat(4)5.99%

Max EPS beat(4)53.15%

EPS beat(8)7

Avg EPS beat(8)16.86%

EPS beat(12)10

Avg EPS beat(12)17.48%

EPS beat(16)12

Avg EPS beat(16)13.8%

Revenue beat(2)1

Avg Revenue beat(2)-8.7%

Min Revenue beat(2)-19.48%

Max Revenue beat(2)2.07%

Revenue beat(4)3

Avg Revenue beat(4)60.74%

Min Revenue beat(4)-19.48%

Max Revenue beat(4)214.6%

Revenue beat(8)5

Avg Revenue beat(8)174.75%

Revenue beat(12)6

Avg Revenue beat(12)123.62%

Revenue beat(16)10

Avg Revenue beat(16)199.78%

PT rev (1m)-10.61%

PT rev (3m)-18.06%

EPS NQ rev (1m)3.66%

EPS NQ rev (3m)-10.84%

EPS NY rev (1m)0%

EPS NY rev (3m)-70.19%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-14.75%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-15.77%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	7.72
P/FCF	N/A
P/OCF	N/A
P/B	3.35
P/tB	3.35
EV/EBITDA	N/A

EPS(TTM)-0.21

EYN/A

EPS(NY)-0.05

Fwd EYN/A

FCF(TTM)-0.32

FCFYN/A

OCF(TTM)-0.32

OCFYN/A

SpS0.18

BVpS0.42

TBVpS0.42

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.72%
ROE	-51.83%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	97.88%
FCFM	N/A

ROA(3y)-50.19%

ROA(5y)-45.98%

ROE(3y)-104.64%

ROE(5y)-88.33%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.87
Quick Ratio	6.97
Altman-Z	-2.18

F-Score4

WACC8.45%

ROIC/WACCN/A

Cap/Depr(3y)94.77%

Cap/Depr(5y)125.95%

Cap/Sales(3y)140.92%

Cap/Sales(5y)119.57%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)40%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.67%

EPS Next Y51.86%

EPS Next 2Y35.39%

EPS Next 3Y29.21%

EPS Next 5Y40.11%

Revenue 1Y (TTM)22393.81%

Revenue growth 3Y281.2%

Revenue growth 5Y178.45%

Sales Q2Q%12927.3%

Revenue Next Year163.93%

Revenue Next 2Y102.27%

Revenue Next 3Y80.35%

Revenue Next 5Y64.14%

EBIT growth 1Y36.04%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year74.41%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-45.46%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-46.19%

OCF growth 3YN/A

OCF growth 5YN/A

GERON CORP (GERN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens